COVID-19相关凝血病中的内皮病:单中心横断面研究证据
该单中心横断面研究于2020年4月13日至24日纳入68例实验室确诊COVID-19住院成人患者(ICU 48例、非ICU 20例)及13例无症状非住院对照,评估内皮细胞和血小板活化标志物。ICU患者血管性血友病因子抗原和可溶性P-选择素显著高于非ICU患者,可溶性血栓调节蛋白>3.26 ng/mL与较低的出院率和生存率相关。
要点
- ICU患者VWF抗原均值565%(SD 199)vs 非ICU 278%(133),p<0.0001。
- 可溶性血栓调节蛋白>3.26 ng/mL者出院率22/25(88%)vs 13/25(52%),p=0.0050。
- 可溶性血栓调节蛋白>3.26 ng/mL者Kaplan-Meier生存分析HR 5.9(95%CI 1.9-18.4),p=0.0087。
核心结论
- 研究发现COVID-19中存在内皮病,且可能(likely)与危重病情和死亡相关。
- 早期识别内皮病及减轻其进展的策略可能(might)改善COVID-19结局。
研究设计与样本
- 单中心横断面研究,于2020年4月13日至24日纳入68例实验室确诊COVID-19住院成人(≥18岁)患者,其中ICU 48例、非ICU 20例。
- 另招募13例无症状非住院对照,用于无参考范围生物标志物的比较。
主要发现
- ICU患者VWF抗原均值565%(SD 199)vs 非ICU患者278%(133),p<0.0001;可溶性P-选择素15.9 ng/mL(SD 4.8)vs 11.2 ng/mL(SD 3.1),p=0.0014。
- 20例非ICU患者中16例(80%)VWF抗原浓度高于正常范围。
- 全部患者中死亡率与VWF抗原(r=0.38,p=0.0022)及可溶性血栓调节蛋白(r=0.38,p=0.0078)显著相关。
- 全部患者中可溶性血栓调节蛋白>3.26 ng/mL者出院率22/25(88%)vs 13/25(52%),p=0.0050;Kaplan-Meier生存分析HR 5.9(95%CI 1.9-18.4),p=0.0087。
关键数值与推荐
- VWF抗原高于正常范围:非ICU患者16/20(80%)。
- 可溶性血栓调节蛋白阈值3.26 ng/mL,高于此值与较低出院率及较低生存可能性相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An important feature of severe acute respiratory syndrome coronavirus 2 pathogenesis is COVID-19-associated coagulopathy, characterised by increased thrombotic and microvascular complications. Previous studies have suggested a role for endothelial cell injury in COVID-19-associated coagulopathy. To determine whether endotheliopathy is involved in COVID-19-associated coagulopathy pathogenesis, we assessed markers of endothelial cell and platelet activation in critically and non-critically ill patients admitted to the hospital with COVID-19. METHODS: In this single-centre cross-sectional study, hospitalised adult (≥18 years) patients with laboratory-confirmed COVID-19 were identified in the medical intensive care unit (ICU) or a specialised non-ICU COVID-19 floor in our hospital. Asymptomatic, non-hospitalised controls were recruited as a comparator group for biomarkers that did not have a reference range. We assessed markers of endothelial cell and platelet activation, including von Willebrand Factor (VWF) antigen, soluble thrombomodulin, soluble P-selectin, and soluble CD40 ligand, as well as coagulation factors, endogenous anticoagulants, and fibrinolytic enzymes. We compared the level of each marker in ICU patients, non-ICU patients, and controls, where applicable. We assessed correlations between these laboratory results with clinical outcomes, including hospital discharge and mortality. Kaplan-Meier analysis was used to further explore the association between biochemical markers and survival. FINDINGS: 68 patients with COVID-19 were included in the study from April 13 to April 24, 2020, including 48 ICU and 20 non-ICU patients, as well as 13 non-hospitalised, asymptomatic controls. Markers of endothelial cell and platelet activation were significantly elevated in ICU patients compared with non-ICU patients, including VWF antigen (mean 565% [SD 199] in ICU patients vs 278% [133] in non-ICU patients; p<0·0001) and soluble P-selectin (15·9 ng/mL [4·8] vs 11·2 ng/mL [3·1]; p=0·0014). VWF antigen concentrations were also elevated above the normal range in 16 (80%) of 20 non-ICU patients. We found mortality to be significantly correlated with VWF antigen (r = 0·38; p=0·0022) and soluble thrombomodulin (r = 0·38; p=0·0078) among all patients. In all patients, soluble thrombomodulin concentrations greater than 3·26 ng/mL were associated with lower rates of hospital discharge (22 [88%] of 25 patients with low concentrations vs 13 [52%] of 25 patients with high concentrations; p=0·0050) and lower likelihood of survival on Kaplan-Meier analysis (hazard ratio 5·9, 95% CI 1·9-18·4; p=0·0087). INTERPRETATION: Our findings show that endotheliopathy is present in COVID-19 and is likely to be associated with critical illness and death. Early identification of endotheliopathy and strategies to mitigate its progression might improve outcomes in COVID-19. FUNDING: This work was supported by a gift donation from Jack Levin to the Benign Hematology programme at Yale, and the National Institutes of Health.
引用
- Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020. PMID: 32619411. doi:10.1016/S2352-3026(20)30216-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。